About Head and Neck Cancers

The Mount Sinai Health System is globally recognized for its minimally- invasive treatments and world- renowned head and neck specialists Dr. Eric Genden, Chair of the Department of Otolaryngology – Head and Neck Surgery was the first to perform transoral robotic surgery (TORS) for oropharyngeal cancers in New York State in 2009. Mount Sinai’s Head and Neck Institute, a Center of Excellence for Head and Neck Cancer Head and Neck Cancer Program features a multidisciplinary team offering patients robotic and minimally invasive treatments, as well as the most current options for immunotherapy and clinical trials.

This leading team of head and neck cancer physicians treats:

  • Larynx cancer
  • Oral cancer
  • Parathyroid cancer
  • Salivary gland disorders and cancer
  • Sinus cancer
  • Skin cancers of the face
  • Throat cancer
  • Thyroid disorders and cancer
  • Tracheal cancer 

Multidisciplinary Head and Neck Cancer Care Team

Head and neck cancers are complex diseases, which affect various structures of the mouth, jaw and throat. The delicate nature of these structure and goal of preservation of each is why you or your loved one will needs a team of specialists. Our care philosophy incorporates this team approach at each phase of your care.

A coordinator with our Patient First Program works with the multidisciplinary team to coordinate, your care of our and collaborate with you and your referring physician to identify the best approach for your care. Team members include head and neck surgeons, microvascular and reconstructive surgeons, oral and maxillofacial surgeons, medical and radiation oncologists, oncology nurse practitioners and nurses, speech and hearing therapists, social workers and nutritionists.

Innovative Head and Neck Cancer Research

Mount Sinai offers you and your loved one access to the latest therapies through clinical trials. Physicians and researchers at our Head and Neck Cancer Research Program are studying immunotherapies, the reduction of medical oncology after transoral robotic surgery (TORS), the transmission of human papillomavirus (HPV) and its effect on oropharyngeal cancers, the reduction in side effects, the quality of life with TORS versus open surgery, and the correlation of environmental toxins and thyroid cancer. Our distinguished research program is also internationally recognized as a leading resource for tumor cell dormancy research.

Why Choose Mount Sinai for Head and Neck Cancer Care

At Mount Sinai, our patients have the following distinct care advantages:

  • Expert minimally- invasive head and neck surgeons
  • State-of-the-art technology, including transoral robotic surgery (TORS) and sialendoscopy
  • Microvascular, reconstructive and oral and maxillofacial surgeons
  • Unmatched experience with HPV-related oropharyngeal cancers
  • Multidisciplinary team approach 
  • Medical and Radiation Oncology Surveillance Program during and after treatment
  • Participation in clinical trials, as appropriate
  • Easy access to care, including participation in most insurance plans

To make an appointment: